🚀 VC round data is live in beta, check it out!
Saniona Valuation Multiples
Discover revenue and EBITDA valuation multiples for Saniona and similar public comparables like Camp4 Therapeutics, Keros Therapeutics, Fennec Pharmaceuticals, Nuvectis Pharma and more.
Saniona Overview
About Saniona
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
Founded
2011
HQ
Employees
22
Website
Sectors
Financials (LTM)
EV
$169M
Saniona Financials
Saniona reported last 12-month EBITDA of $23M.
In the same LTM period, Saniona generated $23M in EBITDA and $24M in net income.
Revenue (LTM)
Saniona P&L
In the most recent fiscal year, Saniona reported revenue of $47M and EBITDA of $35M.
Saniona expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $47M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $47M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 99% | XXX | XXX | XXX |
| EBITDA | $23M | XXX | $35M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 73% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 63% | XXX | XXX | XXX |
| Net Profit | $24M | XXX | $31M | XXX | XXX | XXX |
| Net Margin | — | XXX | 67% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Saniona Stock Performance
Saniona has current market cap of $233M, and enterprise value of $169M.
Market Cap Evolution
Saniona's stock price is $1.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $169M | $233M | -2.2% | XXX | XXX | XXX | $0.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSaniona Valuation Multiples
Saniona trades at 3.6x EV/Revenue multiple, and 7.3x EV/EBITDA.
EV / Revenue (LTM)
Saniona Financial Valuation Multiples
As of April 19, 2026, Saniona has market cap of $233M and EV of $169M.
Equity research analysts estimate Saniona's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Saniona has a P/E ratio of 9.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $233M | XXX | $233M | XXX | XXX | XXX |
| EV (current) | $169M | XXX | $169M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 7.3x | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBIT | 7.5x | XXX | 5.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.6x | XXX | XXX | XXX |
| P/E | 9.7x | XXX | 7.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 7.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Saniona Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Saniona Margins & Growth Rates
Saniona's revenue in the last fiscal year grew by 30%.
Saniona's revenue per employee in the last FY averaged $2.1M, while opex per employee averaged $0.8M for the same period.
Saniona Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 73% | XXX | XXX | XXX |
| EBITDA Growth | (60%) | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Saniona Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Saniona | XXX | XXX | XXX | XXX | XXX | XXX |
| Camp4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Keros Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Fennec Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Nuvectis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Egetis Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Saniona M&A Activity
Saniona acquired XXX companies to date.
Last acquisition by Saniona was on XXXXXXXX, XXXXX. Saniona acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Saniona
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSaniona Investment Activity
Saniona invested in XXX companies to date.
Saniona made its latest investment on XXXXXXXX, XXXXX. Saniona invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Saniona
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Saniona
| When was Saniona founded? | Saniona was founded in 2011. |
| Where is Saniona headquartered? | Saniona is headquartered in United States. |
| How many employees does Saniona have? | As of today, Saniona has over 22 employees. |
| Who is the CEO of Saniona? | Saniona's CEO is Thomas Feldthus. |
| Is Saniona publicly listed? | Yes, Saniona is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Saniona? | Saniona trades under SANION ticker. |
| When did Saniona go public? | Saniona went public in 2014. |
| Who are competitors of Saniona? | Saniona main competitors are Camp4 Therapeutics, Keros Therapeutics, Fennec Pharmaceuticals, Nuvectis Pharma. |
| What is the current market cap of Saniona? | Saniona's current market cap is $233M. |
| What is the current revenue of Saniona? | Saniona's last fiscal year revenue is $47M. |
| What is the current EV/Revenue multiple of Saniona? | Current revenue multiple of Saniona is 3.6x. |
| Is Saniona profitable? | Yes, Saniona is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Saniona? | Saniona's last 12 months EBITDA is $23M. |
| What is the current EV/EBITDA multiple of Saniona? | Current EBITDA multiple of Saniona is 7.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.